Potential Drug-Drug Interactions in Heart Failure Patients

Georgiev, Kaloyan; Hvarchanova, Nadezhda; Georgieva, Marieta; Kanazirev, Branimir

doi:10.22159/ijpps.2019v11i9.33585

Cited by 4 publications

(4 citation statements)

References 27 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…and can significantly harm the patient's health. 17,20,21 Pharmacokinetic drug interactions occur when a drug alters absorption, distribution or elimination (disposition) of a simultaneously administered drug, leading to changes in its plasma concentration levels. 5 As mentioned in the result section, relatively small amount of pPKDDIs (216 or 12,4% of all pDDIs) were recognized by the software program.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Both polypharmacy and potential drug-drug interactions (pDDIs), especially those at the pharmacokinetic level, are common in hospitalized patients and are associated with adverse effects and failure of therapy; Objective: The aim of the present study is to investigate retrospectively the prevalence of polypharmacy and the risk of potential pharmacokinetic drug-drug interaction among hospitalized patients; Methods: The medical documentation of hospitalized patients in the unit of internal diseases at the hospital “St Marina” in Varna, Bulgaria for a period of six months (January–July 2016) was retrospectively reviewed. Lexicomp® Drug Interaction software was used for the detection of pDDI. Descriptive statistic and logistic regression were used for data analysis; Results: In this study, 294 patients out of 510 (57%) were selected with polypharmacy. The number of detected potential pharmacokinetic DDIs (pPKDDIs) was only 216 (or 12,4%), but almost 40% of patients with polypharmacy were exposed to at least one pPKDDIs. The most common pPKDDIs occur at the biotransformation level – 78 (36,1%), and the most common enzyme form that is involved in these interactions is cytochrome 3A4 (44 or 20,4%). The number of prescribed medications (>7) was found to increase the possibility of having pDDIs (OR 25.535, 95% CI 12.529 to 52.042; p = <0.001) and pPKDDIs (OR 5.165, 95% CI 3.430 to 7.779; p = <0.001) as well; Conclusion and Relevance: Caution should be taken in patients taking more than seven drugs and careful assessment of the pPKDDIs should be made. When such interactions are detected, they need to be properly evaluated and managed.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…A review of patient prescriptions for potential adverse drug-drug interactions should be performed by using a proper software and/or clinical pharmacists experienced in drug interactions. In addition, it is necessary to monitor patients' responses and related side effects to find adverse interaction reactions [13].…”

Section: Potential Clinical Implicationmentioning

confidence: 99%

Risk of Adverse Drug-Drug Interactions in Heart Failure Patients with Co-morbidity Chronic Kidney Disease Prescribed Polypharmacy

Suryaman,

Bakhriansyah,

Yustikasari

et al. 2023

BIO Web Conf.

View full text Add to dashboard Cite

Heart failure (HF) is a complex clinical syndrome due to the impairment of myocardial function, valvular or pericardial diseases, or anything interfering blood flow leading to fluid retention. A comorbidity that can accompany HF patients is chronic kidney disease (CKD). This condition requires consumption of several drugs simultaneously (polypharmacy). This study aimed to determine the risk of adverse drug-drug interactions in HF patients with co-morbid CKD prescribed polypharmacy. This is an analytic observational study with a cross-sectional approach in the Cardiac Outpatient Clinic of Ulin Public Hospital, Banjarmasin using medical records from 2020-2021. The interactions were determined using the UpToDate® under the Lexicomp tool. Prevalence Odds Ratio (POR) and 95% Confidence Intervals (95%CI) were determined using Logistic Regression analysis. Of 27 patients, 17 were males (62.96%). Most of the interactions (92.92%) were under category C and the moderate category (82 interactions, 82.83%). For HF patients with CKD, polypharmacy increased the risk of adverse drug-drug interactions by 2.75 times compared to those who were not prescribed polypharmacy, but it was not statistically significant (crude POR 2.75, 95% CI; 0.248-30.512). In conclusion, there is no significant relationship between polypharmacy and the risk of adverse drug-drug interactions in HF patients with CKD.

show abstract

“…Furthermore, beta-blockers are commonly used in angina prevention and lowering of blood pressure resulting in slowing down of heartbeat to improve blood flow. Glycoside is used to treat individual with congestive heart failure to stimulate contractility [72].…”

Section: Treatment Against Ischemic Heart Diseasementioning

confidence: 99%

Review: Ischemic Heart Disease and the Potential Role of Fenugreek (Trigonella Foenum Graecum Linn.) in Cardioprotection

et al. 2022

View full text Add to dashboard Cite

Ischemic heart disease, often known as coronary heart disease (CHD), is a term for heart disorders caused by narrowing heart arteries (coronary arteries) that provide blood to the heart's muscles. The body is prone to heart attacks when there is less oxygen supply (hypoxia) to the heart resulting a major cell death in the heart tissues. Cardiovascular disease (CVD) is the leading cause of death worldwide. Over the last few decades, the potential therapeutic effects of herbs and other types of complementary medicines for managing risk factors for CVD have gotten a lot of attention. Fenugreek (Trigonella foenum graecum Linn.) is a very important spice in most Asian dishes. In Malaysia, fenugreek, locally known as ‘halba’, is used in the preparation of popular dishes; ‘nasi dagang’ for breakfast, and ‘putu halba’ as snacks for hi-tea and sometimes applied in drinks. Although, to date, the effect of fenugreek against diabetes and heart diseases is well investigated, most studies do not focus on its the effects at molecular levels. This review gives an insight on the ischemic heart disease and the nutritional values of fenugreek as functional food in protecting the heart.

show abstract

Potential Drug-Drug Interactions in Heart Failure Patients

Cited by 4 publications

References 27 publications

Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics

Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics

Risk of Adverse Drug-Drug Interactions in Heart Failure Patients with Co-morbidity Chronic Kidney Disease Prescribed Polypharmacy

Review: Ischemic Heart Disease and the Potential Role of Fenugreek (Trigonella Foenum Graecum Linn.) in Cardioprotection

Contact Info

Product

Resources

About